Literature DB >> 16696148

Lenalidomide and venous thrombosis in multiple myeloma.

S Vincent Rajkumar, Emily Blood.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16696148

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  17 in total

1.  Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232).

Authors:  Jeffrey A Zonder; John Crowley; Mohamad A Hussein; Vanessa Bolejack; Dennis F Moore; Brock F Whittenberger; Muneer H Abidi; Brian G M Durie; Bart Barlogie
Journal:  Blood       Date:  2010-09-27       Impact factor: 22.113

2.  Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study.

Authors:  Sigurdur Y Kristinsson; Ruth M Pfeiffer; Magnus Björkholm; Lynn R Goldin; Sam Schulman; Cecilie Blimark; Ulf-Henrik Mellqvist; Anders Wahlin; Ingemar Turesson; Ola Landgren
Journal:  Blood       Date:  2010-03-18       Impact factor: 22.113

Review 3.  From clinical trials to clinical practice: single-agent carfilzomib adverse events and their management in patients with relapsed and/or refractory multiple myeloma.

Authors:  David S Siegel
Journal:  Ther Adv Hematol       Date:  2013-12

4.  Comparison of serious adverse reactions between thalidomide and lenalidomide: analysis in the French Pharmacovigilance database.

Authors:  Pascale Olivier-Abbal; Anne-Charlotte Teisseyre; Jean-Louis Montastruc
Journal:  Med Oncol       Date:  2013-09-28       Impact factor: 3.064

Review 5.  Lenalidomide in myeloma.

Authors:  Seema Singhal; Jayesh Mehta
Journal:  Curr Treat Options Oncol       Date:  2007-04

6.  A phase II study of thalidomide and irinotecan for treatment of glioblastoma multiforme.

Authors:  Camilo E Fadul; Linda S Kingman; Louise P Meyer; Bernard F Cole; Clifford J Eskey; C Harker Rhodes; David W Roberts; Herbert B Newton; J Marc Pipas
Journal:  J Neurooncol       Date:  2008-07-26       Impact factor: 4.130

7.  Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines.

Authors:  Shaji K Kumar; Joseph R Mikhael; Francis K Buadi; David Dingli; Angela Dispenzieri; Rafael Fonseca; Morie A Gertz; Philip R Greipp; Suzanne R Hayman; Robert A Kyle; Martha Q Lacy; John A Lust; Craig B Reeder; Vivek Roy; Stephen J Russell; Kristen E Detweiler Short; A Keith Stewart; Thomas E Witzig; Steven R Zeldenrust; Robert J Dalton; S Vincent Rajkumar; P Leif Bergsagel
Journal:  Mayo Clin Proc       Date:  2009-12       Impact factor: 7.616

Review 8.  Lenalidomide in myelodysplastic syndrome and multiple myeloma.

Authors:  Sachin R Shah; Thu M Tran
Journal:  Drugs       Date:  2007       Impact factor: 9.546

9.  Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasias.

Authors:  Aldo M Roccaro; Irene M Ghobrial; Simona Blotta; Steven P Treon; Michele Malagola; Kenneth C Anderson; Paul G Richardson; Domenico Russo
Journal:  Biologics       Date:  2008-09

Review 10.  New therapies in multiple myeloma.

Authors:  F Merchionne; F Perosa; F Dammacco
Journal:  Clin Exp Med       Date:  2007-10-03       Impact factor: 3.984
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.